Candesartan

Candesartan is a medication of the angiotensin II receptor blocker (ARB) class, also called an angiotensin receptor antagonist ^[1]. It is administered by mouth as candesartan cilexetil, an inactive prodrug that is converted to the active compound as it is absorbed from the gut, and it is sold under brand names including Atacand ^[2]. Developed in Japan under the code TCV-116 and brought to market in the late 1990s by Takeda and Astra, candesartan is a long-acting agent used chiefly for high blood pressure and heart failure ^[1][2].

The drug is a selective blocker of the angiotensin II type 1 (AT1) receptor, binding tightly and coming off the receptor only slowly, which gives it a durable, once-daily action ^[1]. By occupying this receptor it prevents the hormone angiotensin II from constricting blood vessels and from stimulating the release of aldosterone, so blood vessels relax, the body retains less salt and water, and blood pressure falls ^[1][2].

In hypertension, candesartan lowers blood pressure effectively with a side-effect profile close to that of placebo ^[1]. The SCOPE study in older adults with elevated blood pressure found that candesartan-based treatment significantly reduced the rate of nonfatal stroke, and separate trial data suggested that candesartan may lower the chance of developing new-onset diabetes compared with some older antihypertensive drugs ^[4]. These findings positioned it as a well-tolerated option across the spectrum of cardiovascular risk, from early hypertension and left ventricular hypertrophy to established heart disease ^[2].

Much of candesartan's evidence comes from the CHARM program, a set of large randomized trials in patients with chronic heart failure ^[1]. These showed that candesartan reduced cardiovascular deaths and hospital admissions for heart failure across a broad range of patients: it benefited those who could not tolerate an angiotensin-converting enzyme (ACE) inhibitor, added further benefit when given on top of an ACE inhibitor, and reduced heart failure hospitalizations in people whose hearts pumped with preserved ejection fraction ^[1][3].

Beyond the cardiovascular system, candesartan has been studied for migraine prevention; a randomized, placebo-controlled trial reported that it reduced the number of days with headache and migraine, establishing ARBs as a prophylactic option for some patients ^[5]. The most common adverse effects are dizziness and low blood pressure, particularly in people who are dehydrated, along with the potential for elevated blood potassium and changes in kidney function. Like all drugs that act on the renin-angiotensin system, candesartan can harm the developing fetus and is contraindicated in pregnancy. It is a prescription medicine taken under medical supervision ^[2].

Candesartan is prescription only and generally well tolerated. Common effects are dizziness and low blood pressure, especially after the first dose or in dehydrated patients. Because it blunts aldosterone, it can raise potassium, so levels are checked, particularly alongside potassium supplements, spironolactone, or NSAIDs. It can reduce kidney function in people with narrowed renal arteries and is monitored with blood tests. It must not be used in pregnancy, where it can seriously harm or kill the fetus, and it should not be combined with ACE inhibitors or the renin inhibitor aliskiren because of added kidney and potassium risk. Angioedema is a rare but serious reaction.

Candesartan blocks the angiotensin II type 1 receptor, and its interactions follow the physiology rather than any cytochrome pathway. Adding a potassium-sparing diuretic, a potassium supplement, a salt substitute or trimethoprim raises the risk of hyperkalemia, since angiotensin blockade already reduces aldosterone-driven potassium excretion.

The most dangerous pairing is with a second agent acting on the same axis. Combining candesartan with an ACE inhibitor or with aliskiren increases hypotension, hyperkalemia and acute kidney injury without improving outcomes; aliskiren is contraindicated alongside candesartan in diabetes.

NSAIDs, including selective COX-2 inhibitors, blunt the antihypertensive effect, and in older or volume-depleted people the combination of candesartan, an NSAID and a diuretic can precipitate acute renal failure.

Candesartan also raises serum lithium, apparently by reducing proximal tubular sodium reabsorption so that lithium is reabsorbed in its place. Lithium toxicity has been reported repeatedly with this combination, sometimes only after several weeks.

Checking a whole stack? Run it through interactions + stacks.

Candesartan belongs to the angiotensin II receptor blocker class, a family born after the 1995 arrival of losartan proved that blocking the AT1 receptor could lower blood pressure without the cough that troubled ACE inhibitors. It was developed by the Japanese pharmaceutical company Takeda, which engineered it as the prodrug candesartan cilexetil so that an otherwise poorly absorbed molecule could be taken by mouth and converted to the active drug in the gut wall.

Candesartan reached the United States market in 1998 under the brand name Atacand, positioned as a once-daily agent notable for its tight and long-lasting grip on the receptor. Its reputation broadened with the CHARM program, reported in 2003, which established a survival and hospitalization benefit in chronic heart failure. A striking side chapter came from neurology, where a Norwegian randomized trial in 2003 found that this blood-pressure drug was also effective for migraine prevention, opening an unexpected line of research.

Candesartan is well regarded as one of the cleaner, more potent members of the ARB class, often singled out for how firmly and durably it blocks the angiotensin II type 1 receptor, which translates into smooth 24-hour blood-pressure control from a single daily dose. Physicians appreciate that it is generally very well tolerated, sharing the class's freedom from the dry cough of ACE inhibitors while carrying solid outcome evidence behind it.

According to PubMed, the CHARM-Overall programme showed candesartan reduced cardiovascular deaths and heart-failure hospitalizations in patients with chronic heart failure, giving it a place beyond simple hypertension [Pfeffer et al., 2003, https://doi.org/10.1016/s0140-6736(03)14282-1]. It has also earned a following in headache medicine, where controlled data support its use as a migraine preventive, an appealing versatility for a single tablet. Honestly, like all drugs acting on this hormone system, it requires attention to kidney function and potassium and is not used in pregnancy, but within those bounds its balance of efficacy and tolerability is highly valued.